Request A Poster

Requestee Name

Requestee Email

Available Posters (SPN-810)

An Electronic Observer-Reported Outcomes Instrument (IA Diary) to Measure Impulsive Aggression in Children With Optimally Treated Attention-Deficit/Hyperactivity Disorder

Battery of Reproductive Toxicology Studies Supporting the Safety of a Dopamine Receptor Antagonist, Molindone

Efficacy and Safety of Extended-Release Molindone (SPN-810) to Treat Impulsive Aggression in Children Being Optimally Treated for Their Attention-Deficit/Hyperactivity Disorder: Phase 2b and Open-Label Extension Results

Long-Term Efficacy and Safety of Extended-Release Molindone (SPN-810) to Manage Impulsive Aggression in Children with Attention-Deficit/Hyperactivity Disorder (ADHD)

Available Posters (Qelbree)

Assessment of Pediatric Weight and Height Trajectories During Long-term Viloxazine ER (Qelbree®) Treatment: Interim Results from an Open-label Extension Trial in ADHD

Efficacy of viloxazine ER in treating defiant/aggressive and risky decision-making behaviors in children and adolescents with ADHD

Qelbree® (Viloxazine ER) Efficacy in Adults with ADHD Inattentive or Combined Presentations

Efficacy of Long-Term Treatment with Viloxazine Extended-Release Capsules (Qelbree®) in Adults with Attention-Deficit/Hyperactivity Disorder: Results From an Open-Label Extension

Characterization of Viloxazine’s Serotonergic Effects at Doses Relevant for ADHD Treatment

Assessment of Serotonergic Effects of Viloxazine in Cynomolgus Monkeys Using PET Imaging with the [11C]CIMBI-36 Serotonin Receptor (5-HT2A/2C) Agonist Radioligand

Viloxazine Induces Dose-Dependent Increases in Interstitial Levels of Norepinephrine, Dopamine, and Serotonin in Rat Medial Prefrontal Cortex

Interim Analysis of Efficacy During Long-Term Treatment with Viloxazine Extended-Release Capsules (Qelbree®) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder

The Impact of Viloxazine Extended-Release Capsules (Qelbree®) on Executive Function Assessed via the BRIEF-A in an Open-Label Extension Safety Trial of Adults with Attention-Deficit/Hyperactivity Disorder

Available Posters (Oxtellar XR)

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

A legacy of innovation, a portfolio of promise ™

A legacy of innovation, a portfolio of promise ^™